November 17, 2016 - DoubleTree Hotel - Somerset, NJ
2:00 to 9:00 - Training Workshops 12:00 to 4:30

Innovating Biologics for the Future

Keynote: David Pollard, Ph.D.
Executive Director of BioProcess Technology & Expression, BioProcess Development

Ben Locwin
Business Strategy, Operations, and Performance, 

Arvind Srivastava, Ph.D.
Current Research Advisor, 
Former Director, Formulation Development,
Eli Lilly and Company

Joanne Beck, Ph.D.
EVP Global Pharmaceutical Development and Operations,

Michael Falkow
The Lancer Group

Michael Sarachman
Senior Director, Standards Management & Technology,

Satvik Gadamsetty
Global Technical Operations,


Confirmed Speakers:
Keynote: David Pollard, Ph.D., Merck,  Executive Director, BioProcess Technology & Expression
Joanne Beck, Ph.D., Celgene, EVP, Pharmaceutical Development & Global Manufacturing
Michael Falkow, the Lancer Group
Satvik Gadamsetty, Merck, Global Technical Operations
Ben Locwin, Biogen, Director, Business Strategy, Operations, and Performance
Michael Sarachman, GS1, Senior Director, Standards Management & Technology
Arvind Srivastava, Ph.D., Eli Lilly and Company, Current Research Advisor, Former Director, Formulation Development


While addressing unmet medical needs, pharmaceutical and biotech companies are facing a complex and exciting future. Technological advances in pharmaceutical and biologics manufacturing are stimulating new processes and opening new challenges.

RPM Expo is a marketplace for manufacturing engineers, managers, and front line operators to meet with today’s most innovative and mature service companies. In addition to manufacturing equipment makers, RPM Expo 2016 will bring together decision makers with the resources required to implement evolving solutions in this highly regulated environment.

Pipeline Trends:

It is likely that pharma will focus on new, innovative biologics-- not to the exclusion of small molecules, but as a means to stake out market share for unmet medical needs. Further, there is likely to be a move toward biologicals that combine with small molecule-based therapies or other biologics.  And, while pharma is investing heavily in novel biologics for oncology and other therapeutic areas, traditional generics providers may focus on ramp up for biosimilars.

Increasing Revenue While Cutting Costs:

Nowhere are cost pressures felt more keenly than in groups managing high-volume production of a portfolio of therapies ranging from small molecules to biologics.  These groups seek novel solutions through innovative technologies and business practices (partnerships, sourcing, collaboration).   

Key to the next generation of manufacturing is the flexibility afforded by automation, system-level software, inventory control, and managing partnerships.   Consequently, companies are continually assessing software and systems to optimize processes, facilities, and business process solutions (e.g., ERPs, CMOs).

RPM Expo 2016 is focused on today's most advanced strategies and technologies for manufacturing drugs reproducibly and cost-effectively.